Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 Aug;86(8):761–769. doi: 10.1111/j.1349-7006.1995.tb02466.x

Dipyridamole Combined with Tumor Necrosis Factor‐α Enhances Inhibition of Proliferation in Human Tumor Cell Lines

Nobuo Suzuki 1,✉, Souei Sekiya 2, Isamu Sugano 3, Takayuki Kojima 4, Hideo Yamamori 5, Yoshiaki Takakubo 6
PMCID: PMC5920906  PMID: 7559100

Abstract

In the search for cytokines whose antiproliferative action could be enhanced by combination with dipyridamole, 2,6‐bis(diethanolamino)‐4,8‐dipiperidinopyrimido[5,4,d]pyrimidine, the combination of tumor necrosis factor‐α (TNF‐α) with this agent was evaluated in various human tumor cell lines. Inhibition of the proliferation of human melanoma cell lines MM‐1CB and HMV‐1 by TNF‐α (1–102 U/ml) was enhanced in culture dishes by combination treatment with dipyridamole (0.1–10 μM). The enhancement effect was also detected in other tumor cell lines: T9S (glioma), SCC‐1CB (squamous cell carcinoma), HAC‐2 (ovarian clear‐cell carcinoma), HLE (hepatoma), HEC‐1 (endometrial adenocarcinoma) and HOC‐21 (ovarian serous cystadenocarcinoma). The incorporation of [14C]amino acids and [3H]nridine into acid‐insoluble cell materials in the combination‐treated cells was not significantly different from that in cells treated with TNF‐α or dipyridamole. However, the incorporation of [3H]thymidine was specifically inhibited in all cell lines examined after more than 12 h of the TNF‐α and dipyridamole combination treatment, although neither agent alone inhibited this incorporation. On the other band, the growth of tumors induced by the injection of MM‐1CB and HMV‐1 cells into nude mice was more markedly inhibited by the subcutaneous administration of TNF‐α in combination with orally administered dipyridamole than by either agent alone. The results presented suggested that dipyridamole is beneficial in assuring the effectiveness of anti‐cancer cytokine therapy.

Keywords: Dipyridamole, TNF‐α, Human tumor cells

Full Text

The Full Text of this article is available as a PDF (587.0 KB).

REFERENCES

  • 1. ) Rege , A. A. , Huang , K. and Aggarwal , B. B.Tumor necrosis factor . In “ Cytokine Therapy ,” ed. Galvani D. W. and Cawley J. C. , pp. 152 – 176 ( 1992. ). Cambridge University Press; , New York . [Google Scholar]
  • 2. ) Kojima , T. , Suzuki , N. , Sugano , I. and Hayata , I.Enhancement of an anti‐tumor effect of interferon by dipyridamole in established human malignant melanoma cell strains . Int. J. Cancer , 46 , 853 – 857 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Suzuki , N. , Oiwa , Y. , Sugano , I. , Inaba , N. , Sekiya , S. , Fukazawa , I. , Yoshida , J. , Takakubo , Y. , Isogai , E. and Saito‐Ebihara , M.Dipyridamole enhances an antiproliferative effect of interferon in various types of human tumor cells . Int. J. Cancer , 51 , 627 – 633 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Caine , I. and Eldor , A.Dipyridamole . Harefuah , 111 , 240 – 244 ( 1986. ) ( in Hebrew ). [PubMed] [Google Scholar]
  • 5. ) Batlouni , M.Dipyridamole and ischemic heart disease . Arq. Bras. Cardiol. , 50 , 69 – 74 ( 1988. ). [PubMed] [Google Scholar]
  • 6. ) Shalaev , S. V.Platelet aggregation inhibition in the prevention of myocardial infarction: the results of prospective studies . Kardiologiya , 29 , 116 – 120 ( 1989. ). [PubMed] [Google Scholar]
  • 7. ) Carswell , E. A. , Old , L. J. , Kassel , R. L. , Green , S. , Fiore , N. and Williamson , B.An endotoxin‐induced serum factor that causes necrosis in tumors . Proc. Natl. Acad. Sci. USA , 72 , 3666 – 3670 ( 1975. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Blick , M. , Sherwin , S. A. , Rosenblum , M. and Gutterman , J.Phase I study of recombinant tumor necrosis factor in cancer patients . Cancer Res. , 47 , 2986 – 2989 ( 1987. ). [PubMed] [Google Scholar]
  • 9. ) Wiedenmann , B. , Reichardt , P. , Rath , U. , Theilmann , L. , Schule , B. , Ho , A. D. , Schlick , E. , Kempeni , J. , Hunstein , W. and Kommerell , B.Phase I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas . J. Cancer Res. Clin. Oncol. , 115 , 189 – 192 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Aulitzky , W. E. , Tilg , H. , Gunther , G. , Mull , R. , Flener , R. , Vogel , W. , Herald , M. , Berger , M. , Judmaier , G. and Huber , C.Recombinant tumor necrosis factor α administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial . Eur. J. Cancer , 27 , 462 – 467 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Mittelman , A. , Puccio , C. , Gafney , E. , Coombe , N. , Singh , B. , Wood , D. , Nadler , P. , Ahmed , T. and Arlin , Z.A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5‐day continuous infusion . Invest. New Drugs , 10 , 183 – 190 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Yoshida , J. , Wakabayashi , T. , Mizuno , M. , Sugita , K. , Yoshida , T. , Hori , S. , Mori , T. , Sato , T. , Karashima , A. , Kurisu , K. , Kiya , K. and Uozumi , T.Clinical effect of intra‐arterial tumor necrosis factor‐α for malignant glioma . J. Neurosurg. , 77 , 78 – 83 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Schiller , J. H. , Storer , B. E. , Witt , P. L. , Alberti , D. , Tombes , M. B. , Arzoomanian , R. , Proctor , R. A. , McCarthy , D. , Brown , R. R. , Voss , S. D. , Remick , S. C. , Grem , J. L. , Borden , E. C. and Trump , D. L.Biological and clinical effects of intravenous tumor necrosis factor‐α administered three times weekly . Cancer Res. , 51 , 1651 – 1658 ( 1991. ). [PubMed] [Google Scholar]
  • 14. ) Bocci , V.Central nervous system toxicity of interferons and other cytokines . J. Biol. Regul. Homeost. Agents , 2 , 107 – 118 ( 1988. ). [PubMed] [Google Scholar]
  • 15. ) Piper , B. F. , Rieger , P. T. , Brophy , L. , Haeuber , D. , Hood , L. E. , Lyver , A. and Sharp , E.Recent advances in the management of biotherapy‐related side effects: fatigue . Oncol. Nurs. Forum , 16 , 27 – 34 ( 1989. ). [PubMed] [Google Scholar]
  • 16. ) Orita , K. , Fuchimoto , S. , Kurimoto , M. , Ando , S. and Minowada , J.Early phase II study of interferon‐α and tumor necrosis factor‐α combination in patients with advanced cancer . Acta Med. Okayama , 46 , 103 – 112 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Demetri , G. D. , Spriggs , D. R. , Sherman , M. L. , Arthur , K. A. , Imamura , K. and Kufe , D. W.A phase I trial of recombinant human tumor necrosis factor and interferon‐γ: effects of combination cytokine administration in vivo . J. Clin. Oncol. , 7 , 1545 – 1553 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Kurzrock , R. , Fienberg , B. , Talpaz , M. , Saks , S. and Gutterman , J. U.Phase I study of a combination of recombinant tumor necrosis factor‐α and recombinant interferon‐γ in cancer patients . J. Interferon Res. , 9 , 435 – 444 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Fiedler , W. , Zeller , W. , Peimann , C. J. , Weh , H. J. and Hossfeld , D. K.A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer . Klin. Wochenschr. , 69 , 261 – 268 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Smith , J. W. , Urba , W. J. , Clark , J. W. , Longo , D. L. , Farrell , M. , Creekmore , S. P. , Cordon , K. C. , Jaffe , H. and Steis , R. G.Phase I evaluation of recombinant tumor mecrosis factor given in combination with recombinant interferon‐gamma . J. Immunother. , 10 , 355 – 362 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Yang , S. C. , Grim , E. A. , Parkinson , D. R. , Carinhas , J. , Fry , K. D. , Mendiguren‐Rodriguez , A. , Licciardello , J. , Owen‐Schaub , L. B. , Hong , W. K. and Roth , J. A.Clinical and immunomodulatory effects of combination immunotherapy with low‐dose interleukin 2 and tumor necrosis factor‐α in patients with advanced non‐small cell lung cancer: a phase I trial . Cancer Res. , 51 , 3669 – 3676 ( 1991. ). [PubMed] [Google Scholar]
  • 22. ) Alexander , R. B. , Nelson , W. G. and Coffey , D. S.Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II . Cancer Res. , 47 , 2403 – 2406 ( 1987. ). [PubMed] [Google Scholar]
  • 23. ) Itano , S. , Fuchimoto , S. and Orita , K.The synergistic antitumor effect of natural‐human TNF and anticancer drugs . Hiroshima J. Med. Sci. , 36 , 157 – 161 ( 1987. ). [PubMed] [Google Scholar]
  • 24. ) Regenass , U. , Muller , M. , Curschellas , E. and Matter , A.Antitumor effect of tumor necrosis factor in combination with chemotherapeutic agents . Int. J. Cancer , 39 , 266 – 273 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Watanabe , N. , Niitsu , Y. , Yamauchi , N. , Ohtsuka , Y. , Sone , H. , Neda , H. , Maeda , M. and Urushizaki , I.Synergistic cytotoxicity of recombinant human TNF and various anti‐cancer drugs . Immunopharmacol. Immunotoxicol. , 10 , 117 – 127 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Mutch , D. G. , Powell , C. B. , Kano , M.‐S. and Collins , J. L.In vitro analysis of the anti‐cancer potential of tumor necrosis factor in combination with cis‐platinum . Gynecol. Oncol. , 34 , 328 – 333 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Krosnick , J. A. , Mule , J. J. , McIntosh , J. K. and Rosenberg , S. A.Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vitro . Cancer Res. , 49 , 3729 – 3733 ( 1989. ). [PubMed] [Google Scholar]
  • 28. ) Bonavida , B. , Tsuchitani , T. , Zighelboim , J. and Berek , J.Synergy is documented in vitro with low‐dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells . Gynecol. Oncol. , 38 , 333 – 339 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Cimoli , G. , Valenti , M. , Venturini , M. , Conte , P. and Russo , P.Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells . Anticancer Res. , 12 , 1411 – 1414 ( 1992. ). [PubMed] [Google Scholar]
  • 30. ) Matsuo , S. , Takano , S. , Yamashita , J. and Ogawa , M.Synergistic cytotoxic effects of tumor necrosis factor, interferon‐γ and tamoxifen on breast cancer cell lines . Anticancer Res. , 12 , 1575 – 1580 ( 1992. ). [PubMed] [Google Scholar]
  • 31. ) Schuchter , L. M. , Luginbuhl , W. E. and Meropol , N. J.The current status of toxicity protectants in cancer therapy . Semin. Oncol. , 19 , 742 – 751 ( 1992. ). [PubMed] [Google Scholar]
  • 32. ) Hill , A. D. K. , Redmond , H. P. , Croke , D. T. , Grace , P. A. and Bouchier‐Hayes , D.Cytokines in tumor therapy . Br. J. Surg. , 79 , 990 – 997 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Frei , E. , III. and Spriggs , D.Tumor necrosis factor: still a promising agent . J. Clin. Oncol. , 7 , 291 – 294 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Taguchi , T. and Sohmura , Y.Clinical studies with TNF . Biotherapy , 3 , 177 – 186 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Tsujimoto , M. , Tanaka , S. , Sakuragawa , Y. , Tsuruoka , N. , Funakoshi , K. , Butsugan , T. , Nakazato , H. , Nishihara , T. , Noguchi , T. and Vilcek , J.Comparative studies of the biological activities of human tumor necrosis factor and its derivatives . J. Biochem. , 101 , 919 – 925 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Bachwich , P. R. , Lynch , J. P. , Larrick , J. , Spengler , M. and Kunkel , S. L.Tumor necrosis factor production by human sarcoid alveolar macrophage . Am. J. Pathol. , 125 , 421 – 426 ( 1986. ). [PMC free article] [PubMed] [Google Scholar]
  • 37. ) Watanabe , F. , Kojima , T. , Morita , E. , Kobayashi , M. and Fujita , M.Establishment of a human skin squamous cell carcinoma cell line (SCC‐1CB) in vitro and its characteristics . Jpn. J. Dermatol. , 99 , 793 – 800 ( 1989. ) ( in Japanese ). [PubMed] [Google Scholar]
  • 38. ) Doi , I. , Namba , M. and Sato , J.Establishment and some biological characteristics of human hepatoma cell lines . Gann , 66 , 385 – 392 ( 1975. ). [PubMed] [Google Scholar]
  • 39. ) Tsai , C.‐M. , Gazdar , A. F. , Venzon , D. J. , Steinderg , S. M. , Dedrick , R. L. , Mulshine , J. L. and Kramer , B. S.Lack of in vitro synergy between etoposide and cis‐diammine‐dichloroplatinum(II) . Cancer Res. , 49 , 2390 – 2397 ( 1989. ). [PubMed] [Google Scholar]
  • 40. ) Fuse , A. and Kuwata , T.Effects of interferon on the human clonal cell line, RSa: inhibition of macromolecular synthesis . J. Gen. Virol. , 33 , 17 – 24 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Sugita , K. , Suzuki , N. , Kojima , T. , Tanabe , Y. , Nakajima , H. , Hayashi , A. and Arima , M.Cockayne syndrome with delayed recovery of RNA synthesis after ultraviolet irradiation but normal ultraviolet survival . Pediatr. Res. , 21 , 34 – 37 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 42. ) Sugarman , B. J. , Aggarwal , B. B. , Hass , P. E. , Figari , I. S. , Palladino , M. A. , Jr. and Shepard , H. M.Recombinant human tumor necrosis factor‐α: effects on proliferation of normal and transformed cells in vitro . Science , 230 , 943 – 945 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 43. ) Reis , L. F. L. , Lee , T. H. and Vilcek , J.Tumor necrosis factor acts synergistically with autocrine interferon‐β and increases interferon‐β mRNA levels in human fibroblasts . J. Biol. Chem. , 264 , 16351 – 16354 ( 1989. ). [PubMed] [Google Scholar]
  • 44. ) Pusztai , L. , Lewis , E. C. and McGee , J. O.Growth arrest of the breast cancer cell line, T47D, by TNFα; cell cycle specificity and signal transduction . Br. J. Cancer , 67 , 290 – 296 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. ) Isogai , E. and Suzuki , N.Involvement of antipainsensitive protease activity in suppression of UV‐mutagenicity by human interferon‐α . Mutat. Res. , 325 , 81 – 85 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 46. ) Camussi , G. , Albano , E. , Tetta , C. and Bussolino , F.The molecular action of tumor necrosis factor‐α . Eur. J. Biochem. , 202 , 3 – 14 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 47. ) Casper , E. S. , Baselga , J. , Smart , T. B. , Magill , G. B. , Markman , M. and Ranhosky , A.A phase II trial of PALA+dipyridamole in patients with advanced soft‐tissue sarcoma . Cancer Chemother. Pharmacol. , 28 , 51 – 54 ( 1991. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES